Marketing Authorization Application for Lipsovir® submitted to European regulatory authorities.

Medivir has now submitted an application for marketing authorization to the European regulatory authorities for Lipsovir®, a topical product for prevention and treatment of cold sores.

Lipsovir® is a patented combination of hydrocortisone (an anti-inflammatory agent) and acyclovir (an antiviral agent) in a proprietary cream base developed by Medivir.

The clinical phase III program demonstrated that the development of cold sores can be prevented with early treatment initiation, an effect that currently available products for this indication lack. Lipsovir® thereby provides individuals prone to recurrent cold sores with a clinically important benefit compared to currently available products.

“We have achieved a substantial and important milestone for Lipsovir® in filing registration applications in both USA and Europe”, says Börje Darpö, Head of Medivir’s clinical development department.

For additional information please contact
Rein Piir, CFO & VP, Investor Relations at Medivir, +46 8 5468 3123 or +46 708 537292

For more information on Medivir, please see the company website

About Us

Medivir develops innovative pharmaceuticals for the treatment of cancer. The company specializes within protease inhibitor research and nucleotide/nucleoside science.The research is conducted in all phases of pharmaceutical development, from idea to clinical phase III studies. The development work is conducted both in-house and through partnerships.Medivir is listed on the Nasdaq Stockholm Mid Cap List.


Documents & Links